Neurocrine Biosciences
NBIX
#1397
Rank
A$23.72 B
Marketcap
A$233.43
Share price
0.85%
Change (1 day)
22.72%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2026 (TTM): A$9.99

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is A$9.50. In 2025 the company made an earnings per share (EPS) of A$6.83 an increase over its 2024 EPS that were of A$4.79.

EPS history for Neurocrine Biosciences from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)A$9.9946.39%
2025A$6.8342.6%
2024A$4.7933.07%
2023A$3.6057.76%
2022A$2.2869.47%
2021A$1.35-78.21%
2020A$6.18990%
2019A$0.5781.82%
2018A$0.31-113.5%
2017A-$2.310.62%
2016A-$2.2957.28%
2015A-$1.4625.61%
2014A-$1.1618.84%
2013A-$0.98-1085.71%
2012A$0.09915

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
A$1.86-80.48%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
A$2.91-69.35%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
A$39.98 320.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
A$1.30-86.29%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
A-$2.88-130.25%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
A$5.82-38.75%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
A-$10.69-212.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
A$2.70-71.61%๐Ÿ‡ฌ๐Ÿ‡ง UK